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I.

Introduction
Oxycontin, a schedule II substance, was approved by the Food and Drug Administration

(FDA) in 1995 to treat chronic pain mainly in cancer patients.1 However, in the last fifteen years,
opioids have been prescribed to treat acute pain and chronic pain alike, driving up the amount of
prescribed opioids.2 For instance, in 2012, enough prescriptions of opioids for pain were written
that every adult in the United States could have a full bottle of pills. 3 The unchecked access to
opioid prescriptions led to a surge in the number of deaths from opioid abuse and addition. As it
currently stands, on average 130 Americans die every day from what is known as the opioid
epidemic.4
The more recent federal laws that address the opioid epidemic attempt to improve and
expand upon existing federal laws that address the issue of addiction as well as create new laws
aimed at addressing what President Donald Trump has recently declared to be a public health
emergency.5 States have done their part by implementing programs to help tackle the opioid crisis
in a more comprehensive manner to meet the varying needs of each state.
Society’s perception about opioid addiction has significantly shifted since the time of President
Richard Nixon. There is no longer a “war on drugs” mentality, and incarceration is no longer at
the forefront of any major federal or state resource allocated towards combating the opioid

1

What Is the U.S. Opioid Epidemic?, U.S. Dep't of Health & Hum. Servs., https://www.hhs.gov/opioids/about-theepidemic/ (last visited Oct. 14, 2018).
2
Id.
3
Leonard J. Paulozzi et al., Vital Signs: Variation Among States in Prescribing of Opioid Pain Relievers and
Benzodiazepines - United States, 2012, CDC, 63 MORBIDITY & MORTALITY WKLY. REP. 563 (July 4, 2014).
4
CDC, National Center for Health Statistics, Wide-ranging online data for epidemiologic research (WONDER),
(2017), http://wonder.cdc.gov.
5
Acting Secretary Declares Public Health Emergency to Address National Opioid Crisis, U.S. DEPARTMENT OF
HEALTH & HUMAN SERVS., HHS (Oct. 26, 2017), https://www.hhs.gov/about/news/2017/10/26/hhs-actingsecretary-declares-public-health-emergency-address-national-opioid-crisis.html.
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epidemic.6 While the federal and state response seems promising, the efforts to fight the opioid
epidemic comes with its shortfalls.
The Second part of this paper will introduce federal frameworks that existed before and after
the FDA approved Oxicontin in 1995. Part three will focus on the federal laws passed in response
to the increase in opioid overdose deaths and the public health emergency. Part four will discuss
in depth two major pieces of legislation between the President Barack Obama and President
Donald Trump administration and how they tackle the opioid epidemic with a non-punitive
approach, focusing on opioid addiction as an illness rather than a choice as well as what the new
perspective means for medication-assisted treatment and the resistance by practitioners to adopt
this form of treatment. Part five will discuss the same similar efforts to combat the opioid epidemic
but on a state level and whether the state level programs are helping or harming the cause. Finally,
part six will focus on New Jersey, discussing on how it has become the ‘first’ in terms of the
different types of approaches it has taken to combat the epidemic and what the implications of
these ‘first’ mean in practice, as well as discuss related laws passed to combat the epidemic on a
more local level.
II.

Federal Framework

Food, Drug, and Cosmetic Act of 1938
The public demanded legal quality and identity standards that would prohibit false
therapeutic claims for drugs and manage product advertising among other things. 7 In 1906, the
Wiley Act only regulated product labeling rather than requiring pre-market approval, falling short

6

See Payan, Tony, A War that Can't Be Won, The University of Arizona Press, (2013).
Part II: 1938, Food, Drug, Cosmetic Act, U.S. Food & Drug Admin.,
http://www.fda.gov/AboutFDA/WhatWeDo/History/Origin/ucm054826.html.
7
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of addressing concerns about false or misleading statements as to the curative effects of a drug.8 It
also lacked restriction upon use of poisons in drugs.9
Congressional response came through, and the Food, Drug, and Cosmetic Act was passed
in 1938. Public opinion was a catalyst in the movement towards a change in the law 10 rather than
reliance on amendments to remedy the failings of the existing Act.

11

The new law required that

drugs be labeled with adequate directions for safe use12 and mandated pre-market approval of all
new drugs, such that a manufacturer would have to prove to the Food and Drug Administration
(FDA) that a drug was safe before it could be sold.13 The act required directions and warning labels
on prescription medication to alert the public of the unsafe dosage, methods, or duration of
administration or application. 14 Drug manufacturers were required to provide scientific proof that
new products could be safely used before putting them on the market. 15

Comprehensive Drug Abuse Prevention and Control Act of 1970- Controlled Substance Act
Although Congress found many drugs to have a legitimate medical purpose, it also found
that there was illegal and improper use of these drugs, finding it necessary to establish a
comprehensive system to meet these concerns under a single statute.16 There was public pressure
to increase the penalties for possession of narcotics and drugs that were improperly used.17

8

Vincent A. Kleinfeld, Legislative History of the Federal Food, Drug, and Cosmetic Act, 50 Food & drug L.J.65, 66
(1995).
9
supra note 5.
10
Wallace F. Janssen, The Story of the Laws Behind the Labels, FDA Consumer Magazine, (June 1981).
11
Kleinfeld, supra note 8.
12
21 U.S.C.S. § 352(a).
13
Id. at 352 (a)(1).
14
Id. at 352 (f).
15
Janssen, supra note 10.
16
Lisa N. Sacco, Drug Enforcement in the United States: History, Policy and Trends, Congressional Research
Service (2014), https://fas.org/sgp/crs/misc/R43749.pdf.
17
Janssen, supra note 10 at 12.
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The enforcement of drug laws was originally under the jurisdiction of the FDA in the
Department of Health, Education, and Welfare.

18

This was the beginning of a shift from dealing

with the issues of drug abuse from a concern for public health approach towards punitive, law
enforcement approach.19 For example, the Boggs Act of 1951 set mandatory minimums of prison
sentences for drug convictions, while the Narcotic Control Act of 1956 established mandatory
sentences for possession and sale. 20
The Controlled Substance Act (CSA) of 1970 brought narcotics and dangerous drugs under
a comprehensive scheme of federal control.21 The Bureau of Narcotics, in the Treasury Department
and the Bureau of Drug Abuse Control, in the Department of Health, Education and Welfare (at
the time), were consolidated into the Bureau of Narcotics and Dangerous Drugs that was
established in the Department of Justice, serving what President Nixon called “... notice to the
pusher and the peddler that their criminal acts must stop.”22 In 1973, the Drug Enforcement
Administration (DEA) was established in the Department of Justice23 and became a superagency
in charge of enforcing the operations of criminal and non-criminal regulatory requirements of the
CSA, like requiring persons who handle controlled substances or listed chemicals (including
doctors, hospitals and pharmacies) to register with the DEA.24
CSA regulates the lawful possession, production and distribution of controlled substances
through a system that categorizes substances based on how dangerous they are considered to be,

18

Thomas M. Quinn & Gerald T. McLaughlin, The Evolution of Federal Drug Control Legislation, 22 CATH. U. L.
REV. 586 (1973).
19
Id.
20
Sacco, supra note 16.
21
Reorganization Plan No.1 of 1968,
https://uscode.house.gov/view.xhtml;jsessionid=9C0EBB87FAE7ED08F77CB46DDB85F5D1?path=&req=granulei
d%3AUSC-prelim-title5a-node84-leaf171&f=&fq=&num=0&hl=false&edition=prelim.
22
Id.
23
Executive Order 11727, 38 Fed. Reg. 18,357 (July 6, 1973).
24
Sacco, supra note 16 at 7.
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their potential for abuse and addiction, and whether they have a legitimate medical use. 25 Several
factors considered in determining the control or removal of a drug from the schedules are:
(1) Its actual or relative potential for abuse.
(2) Scientific evidence of its pharmacological effect, if known.
(3) The state of current scientific knowledge regarding the drug or
other substance.
(4) Its history and current pattern of abuse.
(5) The scope, duration, and significance of abuse.
(6) What, if any, risk there is to the public health.
(7) Its psychic or physiological dependence liability.
(8) Whether the substance is an immediate precursor of a substance
already controlled under this subchapter.26
Drugs and substances that are considered controlled under the CSA are placed into one of
five schedules.27 Under schedule I, drugs and substances are classified as having no currently
accepted medical use and a high potential for abuse.28 Some examples of substances within this
schedule include LSD, cannabis, and ecstasy.29 Under schedule II, drugs and substances are
classified as having similarly high potential for abuse with severe dependencies but are nonetheless
accepted for medical use and may be prescribed, dispensed, or administered.30 Examples of these
include morphine, codeine, oxycodone, and fentanyl.31 Schedule III and IV substances are
classified as having less potential for abuse than substances in schedule I or II but still contain
combinations of hydrocodone per dosage unit ranging from 15 milligrams to 90 milligrams per
dosage unit.32 Schedule V substances are classified as having lowest potential for abuse relative to

25

Sacco, supra note 16 at 6.
21 U.S.C.S. § 811(c).
27
Office of Diversion Control, Practitioner's Manual, U.S. Dep't of Justice Drug Enforcement Admin., (2005),
https://www.deadiversion.usdoj.gov/pubs/manuals/pract/section2.htm.
28
Id.
29
Id.
30
Id.
31
Id.
32
Id.
26
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those listed in schedule IV and include cough medicines containing no more than 200 milligrams
of codeine per 100 milliliters.33
The DEA requires the registration of manufacturers, distributors, and dispensers of
controlled substances unless otherwise exempted by law.34 Registration may be revoked or
suspended if it is found that the registrant materially falsified information on the application, if the
registrant is convicted of a felony, if the registrant’s state license has been suspended, revoked, or
denied, or if the registrant has committed acts that would render the registration inconsistent with
the public interest or has been excluded from participation in a program pursuant to section 1128(a)
of the Social Security Act.35 The CSA established a framework for the federal regulation of
controlled substances, thereby addressing drug misuse through the criminal justice system. 36
Anti-Drug Abuse Acts of 1986 and 1988
In an effort to establish a more aggressive enforcement against illicit synthetic drug trade
and improve the federal drug laws by imposing more criminal penalties for simple possession of
controlled substances, in 1986, Congress passed the Anti-Drug Abuse Act.37 The Act is most
notable for its mandatory prison terms on low-level crack offenses.38 The Act required a minimum
sentence of five years for the offenses of possession of cocaine, heroin, crack, fentanyl, and
methamphetamine involving various amounts of weight for each substance.39 The mandatory
minimum sentencing provisions imposed restrictions upon federally appointed judges by

33

Id.
21 C.F.R. §1300.11(a).
35
21 C.F.R. §1301.36; 21 U.S.C. 824(a).
36
Rural Health Information Hub, Module 1: Substance use Disorders in Rural Communities: Historical Treatment
of Substance Use Disorders, https://www.ruralhealthinfo.org/toolkits/substance-abuse/1/historical-treatment.
37
Anti-Drug Abuse Act of 1986. 99 P.L. 570.
38
Deborah J. Vagins & Jesselyn McCurdy, Am. Civil Liberties Union, Cracks in the System: Twenty Years of the
Unjust Federal Crack Cocaine Law, ACLU (2006),
http://www.aclu.org/files/pdfs/drugpolicy/cracksinsystem_20061025.pdf.
39
21 U.S.C. 841(b)(1)(B).
34
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prohibiting alternatives like probation or suspension of the sentence of any person sentenced under
any of the mandatory minimum provisions.40 The Act also provided mandatory minimum penalties
for offenses involving the simple possession of controlled substances.41 Considered to be a
“sweeping legislation” according to the New York Times, the goal of reaching a “drug-free
generation” meant increasing the federal funds available for law enforcement, drug treatment, and
education programs.42 While federal funding was allocated for drug treatment and education
programs, the majority of the funding was for law enforcement.43 Out of the $1.7 billion in
financing, only twelve percent was allocated to the states for educational programs addressing
issues of drug use, while the rest was dedicated to federal and state law enforcement.44
III.

Addressing the “Public Health Emergency”
The response to the opioid epidemic we see today is a shift in how health care providers

treat pain and a shift in how federal and state laws are addressing drug addiction.45 In 1989, the
World Health Organization (WHO) released a statement about the under-treatment of
postoperative and cancer pain patients.46 WHO’s priority was to advocate for effective pain
management of cancer patients.47 It argued that the relief of pain through analgesics was an
essential component of pain management, and that restrictions on stronger opioids could interfere

40

Handbook On The Anti-Drug Abuse Act Of 1986 at 12, U.S. Dept. of Justice - Crim. Div. 63 (1987).
Id.
42
Gerald M. Boyd, Reagan Signs Anti-Drug Measure; Hopes for 'Drug-Free Generation', N.Y. TIMES (Oct. 28,
1986), http://www.nytimes.com/1986/10/28/us/reagan-signs-anti-drug-measure-hopes-for-drug-greegeneration.html.
43
Id.
44
Joel Brinkley, Anti-Drug Law: Words, Deeds, Political Expediency, N.Y. Times (Oct. 27, 1986),
http://www.nytimes.com/1986/10/27/us/anti-drug-law-words-deeds-political-expediency.html.
45
Marcia L. Meldrum, The Ongoing Opioid Prescription Epidemic: Historical Context, 106 AM. J. PUB. HEALTH
1365, 1365 (2016).
46
World Health Organization, Cancer Pain Relief, (1986). Pg. 7-8,
https://apps.who.int/iris/bitstream/handle/10665/43944/9241561009_eng.pdf.
47
Id.
41
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with the necessary use of these drugs.48 Furthermore, the WHO stated that the systems that
regulated the distribution and prescription of opioid drugs were designed before the value of the
oral use of opioid drugs for cancer pain management was recognized.49 There was no intention of
preventing use of opioids for pain relief in cancer.

50

The WHO called upon lawmakers to lift

barriers that would impede the use of drugs that were otherwise necessary for relief of cancer
pain.51 An example of the increase in the liberalization of the use of opioids in the treatment of
pain for cancer patients and chronic non-cancer patients was the FDA’s approval of OxyContin in
1995, an oxycodone controlled release formulation that allowed dosing every 12 hours rather than
immediate release given 4 times daily.52
The Danger of OxyContin, Rise of the Opioid Epidemic
Oxycontin became the center of opioid abuse53 after the FDA approved what would turn
out to be an immediate 12-hour narcotic effect if the opioid was crushed and snorted or injected,
causing overdose or death.54 When approved, the FDA believed that Oxycontin did not have a
greater potential for abuse based on experience with MS Contin, a controlled release formula of
morphine without significant reports of abuse or misuse since the late 1980s.55 Oxycontin was
therefore marketed as being less likely to be abused in comparison to other prescriptions.56

48

Id.
Id. at 27.
50
Id.
51
Id.
52
Art Van Zee, The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy, 99 Am.
J. Pub. Health 221-227 (2009).
53
Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse. FDA.GOV,
https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-eventsaddressing-opioid-misuse-and-abuse.
54
Gardiner Harris, Drug Panel Rejects Please to Curb Sales of a Widely Abused Painkiller, NY Times, (September
11, 2003).
55
Art Van Zee, supra note 52.
56
Caitlin Esch, How One Sentence Helped Set Off the Opioid Crisis, Marketplace: The Uncertain Hour (Dec. 13,
2017), https://www.marketplace.org/2017/12/12/health-care/uncertain-hour/opioid.
49
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However, in a 2004 lawsuit against Purdue Pharma, officials of the company testified in a
deposition that the company never held clinical trials to back up their claim that Oxycontin was in
fact less likely to be an addictive or abused drug.57 Advertising Oxycontin as having a delayed
release that was believed to reduce abuse liability of the drug remained the only label on the
product until 2001 when the FDA removed it and put a black box warning on the drug, signifying
the drug’s serious or life-threatening risks.58 Oxycontin remains one of the most common drugs
involved in prescription opioid overdose deaths to date, accounting for more than 35% of all opioid
overdose death in the U.S. in 2017.59
IV.

Federal Law Responds

Comprehensive Addiction and Recovery Act
Approximately four months before signing into law the Comprehensive Addiction and
Recovery Act (CARA), President Obama shared his remarks at the National Prescription Drug
Abuse and Heroin Summit in Atlanta Georgia, emphasizing the administration’s commitment to
fighting the opioid epidemic.60 “[I]n this global economy of ours that the most important thing we
can do is to reduce demand for drugs. And the only way that we reduce demand is if we're
providing treatment and thinking about this as a public health problem and not just a criminal
problem.”61 In July of 2016, President Obama signed into law the Comprehensive Addiction and
Recovery Act.62 This was the first major federal legislation to address the opioid crisis by taking

57

Id.
Id.
59
Centers for Disease Control and Prevention, Overdose Death Maps: Overdose Deaths Involving Prescription
Opioids, (August 13, 2019), https://www.cdc.gov/drugoverdose/data/prescribing/overdose-death-maps.html.
60
Remarks During a Panel Discussion at the National Prescription Drug Abuse and Heroin Summit in Atlanta,
Georgia (Mar. 29, 2016), http://www.presidency.ucsb.edu/ws/index.php?pid=115136.
61
Id.
62
Comprehensive Addiction and Recovery Act of 2016, Pub. L. No. 114-198, § 201, 130 Stat. 695, 711.
58
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on a comprehensive approach through prevention, treatment, recovery, law enforcement, criminal
justice reform, and overdose reversal.63 The Act expanded and emphasized prevention and
educational efforts aimed particularly at the young population as well as the aging population.64 It
also extended the availability of naloxone, a medication used to block the effects of opioids,
making it possible for law enforcement and first responders to administer it upon arrival at the
scene of an overdose.65 As part of the treatment approach to the opioid epidemic, the Act also
included an amendment to the Controlled Substance Act, increasing the total number of patients a
prescriber can have for the purpose of dispensing buprenorphine from 30 to 100 per year.66
Buprenorphine is a medication that is used in the treatment of adults addicted to opioids and has
been found to be equally effective in promoting treatment of addiction as well as having less
potential for abuse and overdose than methadone.67 The Act also allowed for increased access to
medication-assisted treatment68 of buprenorphine by allowing more health care providers such as
nurse practitioners and physician assistants to prescribe buprenorphine.69
The National Institute on Drug Abuse considers medication-assisted programs to be the
first-line treatment for opioid abuse.70 By providing more access to early intervention and

63

Summary of the Comprehensive Addiction and Recovery Act, Am. Soc'y of Addictive Med.,
https://www.asam.org/advocacy/issues/opioids/summary-of-the-comprehensive-addiction-and-recovery-act.
64
Id.
65
Id.
66
Id.
67
Buprenorphine and the Opioid Crisis: A Primer for Congress. CONGRESSIONAL RESEARCH SERVICE.
R45279.
68
“Medication-assisted treatment (MAT) is the use of Food and Drug Administration (FDA)-approved medication
for the treatment of a specific substance use disorder in combination with clinically indicated behavioral or
cognitive- behavioral counseling and other indicated services. Currently, medications are available to treat tobacco,
alcohol, and OUD, and research is underway to identify effective medications for other substances as well.” Use of
Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings, Substance Abuse and Mental
Health Services Administration.
69
Jeffrey Fudin, Considerations in Expanded Buprenorphine Access for Opioid Abuse Disorder, Pharmacy Times,
(Nov. 17, 2016), https://www.pharmacytimes.com/contributor/jeffrey-fudin/2016/11/considerations-in-expandedbuprenorphine-access-for-opioid-abuse-disorder.
70
Arthur R. Williams & Adam Bisaga, Perspective, From AIDS to Opioids-How to Combat an Epidemic, 375 NEW.
ENGL. J. MED. 813, 813-15 (2016).
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treatment, Medicaid played a central role in the efforts to address the opioid epidemic. 71 The
Affordable Care Act expanded Medicaid coverage for buprenorphine-focused medication-assisted
treatment, enhancing the state capacity to provide for the early intervention and treatment.72
However, despite the increase of federal expansion in prevention, treatment and recovery for
opioid drug abuse, limited availability and challenges in administering medications like
buprenorphine continue to restrict the use of this type of treatment.
First, Medicaid coverage for opioid addiction medications like buprenorphine vary among
states.73 While some states provide Medicaid coverage for a large share of the cost of
buprenorphine, most states’ Medicaid programs pay for a smaller share, putting a majority of the
cost burden directly on the patient.74
Second, the doctor’s fees and time-consuming paperwork does not attract providers to treat
Medicaid enrollees with addictions.75 There is a slow increase in the adoption of medicationassisted treatment because the Centers for Medicare and Medicaid Services (CMS) has not made
maintenance treatments like buprenorphine a mandated benefit.76 CMS finalized framework
establishes a voluntary adoption by sponsors of drug management program for beneficiaries at risk
of misuse or abuse of drugs.77 Yet, a study that surveyed all rural physicians listed as being
registered with the DEA and waived to prescribe buprenorphine as of April 2016, showed that
more than half of the physicians were not actually treating patients with drug addiction.78

71

Medicaid's Role in Addressing the Opioid Epidemic, Kaiser Fam. Found. (Feb. 27, 2018),
https://www.kff.org/infographic/medicaids-role-in-addressing-opioid-epidemic/.
72
Id.
73
Christine Vestal, In Some States, Medicaid rules make it difficult to treat addiction, Stateline PBS, (2016).
74
Id.
75
Id.
76
See Williams & Bisaga supra note 70; See Medicare Part D Opioid Overutilization Strategies for 2019:
Implementation of CARA and Other Policy Guidance. Centers for Medicare and Medicaid Services.
77
Id.
78
Chris Crawford, Overcoming Barriers to Opioid Treatment Takes Center Stage, AAFP (Aug. 11, 2017),
https://www.aafp.org/news/health-of-the-public/20170811opioidsstudy.html.
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Third, while CARA has expanded buprenorphine waivers to nurse practitioners and
physician’s assistant, which has helped address the limited time physicians have to implement a
medication-assisted program,79 underlying barriers remain. For instance, providing the mental
health support services that are in some states required as part of the treatment program has also
caused reluctance among providers to become involved in these kinds of programs.80 Another
reason for the limited adoption in specialty treatment programs is the stigma behind the concept
of taking medications to treat opioid addictions.81 While there is scientific research that has
established that medication-assisted treatment of opioid addiction increases a patients retention
and decreases drug use, infectious disease transmission, and criminal activity,82there has been
significant resistance to the treatment of opioid abuse with medications. 83 Factors that perpetuate
the stigma include, the misconception that opioid use is a moral weakness or willful choice rather
than a medical illness.84

Lifting Some Barriers to Opioid Treatment Programs
In order to overcome the obstacles to using medications to treat drug addiction, there has
to be significant increase in the number of physicians or practitioners willing to adopt a
medication-assisted treatment program.85 According to a 2014 National Survey on Drug Use and
Health, out of 2.27 million individuals who met the criteria for medication-assisted treatment, less

79

Id.
Id.
81
Sarah E. Wakeman &Josiah D. Rich, Barriers to Medications for Addiction Treatment: How Stigma Kills,
Substance Use & Misuse Journal,
https://www.tandfonline.com/doi/abs/10.1080/10826084.2017.1363238?scroll=top&needAccess=true&journalCode
=isum20.
82
NIDA, Medication Assisted Treatment for Opioid Addiction. (Apr. 2012),
http://www.drugabuse.gov/publications/topics-in-brief/medication-assisted-treatment-opioid-addiction.
83
Yngvild Olsen & Joshua M. Sharfstein, Confronting the Stigma of Opioid Use Disorder -- and Its Treatment, 311
JAMA 1393, 1393-1394 (2014).
84
Id.
85
Probuphine: A Game-Changer in fighting Opioid Dependence, National Institute on Drug Abuse (NIDA), (May
26, 2016).
80
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than half of them received some form of medication-assisted treatment.86 One of the barriers
reported was the lack of availability of providers that are adequately trained in addiction
pathophysiology.87 Most medical schools offer limited training programs in addiction treatment,
but the possible solution to this obstacle would be for schools to implement addiction treatment
training as part of the curriculum.88
While treatment is a central pillar of initiatives on combating the opioid problem through
CARA,89 the lack of funding for the programs expanded by CARA hinders CARA from having a
substantial impact on the opioid epidemic.90 Funding for programs extended by CARA relies on
discretionary funds that must be approved every fiscal year, which means that access to
medication-assisted programs is not guaranteed.91 While there has been an increase in overall
spending for treatment and recovery between fiscal year 2017 and 2018,92 Medicaid spending on
opioid treatment drug of buprenorphine has significantly decreased from approximately $150
million between 2016 and 2017 to approximately $9 million between 2017 and 2018.93 Expanding
Medicaid on a state level to cover a larger percentage of the cost of treatment for opioid addiction

86

Richard G. Frank, How do We Finish the Job that the Comprehensive Addiction and Recovery Act Started, Health
Affairs Blog, (September 2016), https://www.healthaffairs.org/do/10.1377/hblog20160912.056506/full/.
87
Id.; Williams & Bisaga, supra note 70.
88
In 2016 the American Board of Medical Specialties recognized addiction medicine as a new subspecialty. Such
acknowledgment shows that the academic medicine community is committed to approaching addiction as a treatable
disease and not perpetuating the stigma of addiction as a moral failing, bad behavior, or a crime. (Robert J. Sokol,
Training Future Physicians to Address Opioid Crisis, Ass’n of American Med. C., (2017)).
89
NIDA, supra note 85.
90
U.S. Department of Health and Human Services (HHS), Office of the Surgeon General, Facing Addiction in
America: The Surgeon General's Report on Alcohol, Drugs, and Health, Washington, DC: HHS, (Nov. 2016).
91
Declaring a “public health emergency” and establishing mandatory spending; “There are two types of spending in
the federal budget process: discretionary and mandatory, where discretionary spending is subject Congress setting
new funding level each fiscal years and mandatory is spending that does not take place through the appropriations
legislation.” (Education Policy, Mandatory and Discretionary Spending, https://www.newamerica.org/educationpolicy/topics/federal-education-legislation-budget/federal-education-budget/federal-budget-process/mandatory-anddiscretionary-spending/).
92
Tracking Federal Funding to Combat the Opioid Crisis 2019, Bipartisan Policy Center, (2019).
93
Id.
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could significantly contribute to the CARA efforts.94 If states rely on congressional grants alone,
then funding for these integral prevention and treatment services falls at the mercy of the standing
administration.

SUPPORT ACT
As part of her Be Best campaign, First Lady Melania Trump, delivered remarks at an
Opioid Town Hall in Las Vegas, Nevada, encouraging people to break through the stereotypes of
drug addiction.95 “Whether it is because of personal use, or that of family members, friends, coworkers or neighbors, opioid addiction is an illness.”96 On October of 2018, President Donald
Trump signed into law the Substance Use Disorder Prevention that Promotes Opioid Recovery and
Treatment for Patients and Communities Act (SUPPORT).97 The administration continued the
initiative to combat the opioid crisis through comprehensive legislation that tackled many aspects
including treatment, recovery, and prevention.98 The majority of the Act’s provisions were
Medicaid related and were aimed at helping states provide much needed coverage and services to
treat opioid addiction, a significant barrier under CARA efforts.99Among the Medicaid-related
provisions, a section of the Act will require covered providers to consult the state drug monitoring
program before prescribing a controlled substance beginning October 1, 2021.100 In addition, the
Act calls for the Secretary of Health and Human Services to devise an action plan that will include

94

Abby Goodnough, Opioid Treatment Is Used Vastly More in States That Expanded Medicaid, N.Y. York Times
(Aug. 21, 2019).
95
The White House, First Lady Melania Trump Attends an Opioid Town Hall in Las Vegas, Nevada, You Tube
(Mar. 12, 2019), https://youtu.be/wThyV5ZFOus.
96
Id.
97
Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities
Act, Pub. L. 115-271, 132 Stat. 3894 (2018) [hereinafter SUPPORT Act].
98
MaryBeth Musumeci & Jennifer Tolbert, Federal Legislation to Address the Opioid Crisis: Medicaid Provisions
in the SUPPORT Act, Henry J. Kaiser Family Found. (Oct. 5, 2018), https://www.kff.org/medicaid/issuebrief/federal-legislation-to-address-the-opioid-crisis-medicaid-provisions-in-the-support-act/.
99
Id.
100
SUPPORT Act, Pub. L. 115-271, 132 Stat. 3894 at § 5042.
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review of potential obstacles to Medicaid and Medicare payment and coverage policies that could
inhibit the effectiveness of the response to the opioid crisis.101 The plan also calls for a review of
beneficiaries’ access to medication-assisted treatment approved by the FDA for the treatment of
opioid use disorder, especially for individuals living in rural or underserved communities.102 This
plan is to be presented to Congress by the Secretary no later than June 1, 2020.103 Furthermore, the
Opioid Quota Reform provision establishes additional mandatory factors that the DEA must
consider when setting the annual opioid quota.104 Factors the DEA Administrator must consider
are:
(1) the total disposal of the controlled substance during the current and two
preceding years
(2) trends in new disposal of the controlled substance;
(3) total inventories (actual or estimated) of “the class and all substances
manufactured from the class [of controlled substances listed in Schedule I or II]”;
(4) projected demand for a particular controlled substance; and
(5) other relevant factors affecting the use of controlled substances, including
changes in the currently accepted medical use of a controlled substance, the
economic and physical availability of the raw materials necessary to produce a
controlled substance, and recent unforeseen emergencies (i.e., natural disasters).105
Section 3282 of SUPPORT amends Section 306 of the CSA to provide that the Attorney General
may, if necessary to avoid the overproduction, shortage, or diversion of a controlled substance,
establish an aggregate or individual production quota by estimating the amount of possible
diversion.106 The Attorney General, in consultation with the Health and Human Services Secretary,
must rely on data of rates of overdose deaths as well as overall public health impact related to the
controlled substance.107 Based on this information, the Attorney General then makes an
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appropriate quota reduction from the quota the Attorney General would have otherwise established
had potential diversion of the controlled substance not been considered.108
SUPPORT also expands the conditions under which a physician may become qualified to
prescribe buprenorphine as part of medication-assisted treatment programs.109 SUPPORT
advances the efforts of CARA in expanding access to medication-assisted treatment by amending
section 303(g) of the CSA to allow physicians to practice in a mediation-assisted treatment
program if the physician graduated in good standing from an accredited U.S. school of allopathic
or osteopathic medicine and received no less than 8 hours of training on treating and managing
opioid-dependent patients, as well as other training that the Secretary deems fit to be included as
part of the osteopathic or allopathic medicine curriculum.110
The SUPPORT Act was passed a year ago and the advantages of the Act seem promising
once all provisions are in full force. There are still lingering concerns that remain unaddressed.
With SUPPORT requiring that PDMPs be consulted prior to any prescription of opioids, more
clinicians may be inclined to not prescribe opioid medication at all.111 Those negatively affected
would be patients who suffer from chronic pain.112 In response to this concern, clinicians are highly
encouraged to address the root of the issue, which is addiction, rather than completely cut off
prescribing opioids.113 The Centers for Disease Control offers a guideline for prescribing opioids
for chronic pain and recommends that in addition to consulting PDMP data, clinicians should also
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be actively engaged in assessing the risks of opioid abuse, addressing the harms, and if necessary,
offer a form of medication-assisted treatment for patients with opioid use disorder.114
V. State Level Response to Opioid Epidemic
Prescription Drug Monitoring Programs
Prescription Drug Monitoring Programs (PDMPs) are state-level electronic databases that
track prescribing and dispensing data of controlled substances and stores them in a centralized
database accessible to authorized users, including prescribers, pharmacists and law enforcement.115
PDMPs are used to help identify patients who may be at risk of prescription misuse or overdose,116
as well as to help identify where the major sources of prescription drug diversion occur by
identifying improper prescribing and dispensing.117 Out of fifty-three types of state agencies that
administer PDMPs, the two most common agencies are Boards of Pharmacy and Departments of
Health, with law enforcement agency trailing right behind.118 The databases for the information
collected from the PDMP in most states are housed within either the licensing or public health
agency, but very few are located within the law enforcement agency.119

Several states have implemented polices that require providers to consult with the state PDMP
before prescribing certain controlled substances in certain circumstances,120 while other states
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leave it to the discretion of the practitioners to decide if they want to refer to the PDMP.121 Access
to the information collected in the PDMP state database varies by state, with most states allowing
practitioners and pharmacists to obtain reports about prescribed substances to patients under their
care.122 Depending on the state, this information may also be available to law enforcement,
licensing and regulatory boards, and state Medicaid programs for Medicaid member or provider
reviews.123 How often data is collected and when it may or must be accessed also varies by state.124
Some states only track prescriptions for schedule II-V controlled medications, while other states
also track uncontrolled medications with a potential for misuse, such as ephedrine.125

Effectiveness of PDMP/ Consistency and Heterogeneity/ Harmful or Helpful?

The rise in opioid overdoses has been the catalyst for more states to implement PDMPs that
support clinical practice and monitoring efforts.126 As of September 2019, forty-nine states, the
District of Columbia, and Guam have operational PDMPs, while Missouri only has a county based
PDMP service.127 While almost the entire country is participating in a unified PDMP, Missouri is
not only suffering the consequences of not being able to monitor possible abuse of opioid
prescriptions but has also attracted an influx of people from neighboring states looking to stock up
on multiple prescriptions.128 Benefits of state level PDMP programs are promising if there is
minimal variation of how the programs are implemented from state to state.
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For example, as mentioned earlier, access to PDMPs is determined by state law.129 However,
the requirement that prescribers or clinicians consult their PDMP vary by state.130 In New Jersey,
direct access to the Prescription Monitoring Program (PMP) is limited to prescribers, delegates
and pharmacists who are licensed by the State of New Jersey, are in good standing with their
respective licensing board and have registered with the private vendor, Appriss, contracted to
maintain the NJPMP.131 However, in New York, the PDMP excludes veterinarians from having
access to the registry and does not require them to consult prior to dispensing or prescribing
controlled substances.132 This variation raises similar concerns of individuals seeking access to
controlled substance prescriptions from neighboring states.133 Although veterinarians prescribe or
dispense opioids for limited uses, there are still concerns of diversion of opioids prescribed to
animals who are presented as ill or injured,134 and the Food and Drug Administration recognizes
that this is a legitimate concern especially when veterinarians are responsible for stocking and
administering these drugs.135

Most states originally made the use of PDMP optional, but as the number of deaths from
overdose have increased throughout the years, most states now require prescribers to register and
consult the databases.136 Despite these trends, heterogeneity among state PDMPs persists.137 For
instance, consulting requirements vary from state to state, thereby increasing the risk of diversion
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through doctor shopping.138 In New Jersey, prescribers are required to consult the PDMP for
information on a patient under specified conditions.139 For example, prescribers must consult the
PDMP if it is the first time the practitioner is prescribing a Schedule II controlled substance to a
new or current patient.140 On the other hand, New York imposes on prescribers a duty to consult
the state PDMP prior to prescribing any controlled substance listed under Schedule II-IV,
regardless if it is the same patient being prescribed the same controlled substance every month.141

Data has shown that use of PDMPs on a state level helps health care professionals in reducing
doctor shopping and overdoses, thereby minimizing the risk of diversion.142 However, the
information gathered and the way of tracking the effectiveness of the program on a national level
is difficult and produces inconsistent results, reflecting in part the heterogeneity of state level
PDMPs.143 It is difficult to determine with some sort of certainty whether differences in PDMPs
across states has a significant impact on the opioid crisis because the use effects of PDMPs remain
mixed.144

Perhaps the most chilling, unintended consequence of implementing a PDMP is that there has
been an increase in the number of heroin overdoses correlated to the implementation of drug
monitoring programs.145 The sharp reduction in access to controlled substances may divert patients
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to seek illicit substances such as heroin, morphine, or fentanyl as an alternative.146 For instance,
Injury Prevention Research Center of the University of North Carolina conducted a study of North
Carolina residents from 2007 through 2013 to determine the ratio of opioid-to-heroin overdose
deaths.147 In January of 2007, for every heroin overdose, there were sixteen opioid deaths, but by
December of 2013, there were 3 opioid deaths for every heroin death.148 This information suggests
that heroin substitution may have increased after the implementation of the state’s PDMP and the
restrictions it imposes on the prescribing practices of opioid.149

Another study similarly indicated that, when the number of opioid prescriptions dropped by
more than fifty percent in the United States between 2012 and 2017,150 the number of opioid deaths
continued to rise as the use of more dangerous, illicit opioids like fentanyl and heroin replaced
once readily accessible prescription opioids.151 While the use of PDMPs aims at reducing the
prescription of opioids for individuals who are misusing opioids, there are many patients who
depend on opioid treatment to manage their pain.152

It is too often that patients with legitimate chronic pain are turned away empty handed as more
prescribers lean on PDMPs as a platform to completely cut off opioid prescriptions to any kind of
patient. PDMPs are intended to be a tool used by prescribers to properly manage patients’ pain,
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talk to them about substance use disorder, and avoid possible risks of abuse, rather than to
completely turn them away from legitimate necessary opioid prescription.153 In September 2019,
the U.S. Department of Health and Human Services published a guide urging clinicians to take
caution on the appropriate manner to implement dosage reduction or discontinuation of long-term
opioid analgesics.154 The guide called for a more “thoughtful, deliberative, collaborative, and
measured manner” when considering reducing or discontinuing opioid analgesics because of the
high risk of acute withdrawal symptoms, exacerbation of pain and potential to seek other sources
of opioids including illicit opioids.155 It is important to recognize that laws that heavily regulate
opioid prescription practices do not necessarily mandate an involuntary dose reduction or
discontinuation.156 Many physicians lack the formal training necessary to help identify prescription
drug abuse which often leads to failure to detect signs of substance abuse and PDMP’s wrongfully
categorizing conscientious physicians as fraudulent prescribers.157 This concern can be addressed
through the implementation of drug addiction education in medical education curriculums as well
as continuing programs.158 Ultimately the treatment decisions for patients with chronic pain should
be left to their doctors and the PDMP programs should not be used as the basis for a complete cut
off from opioid treatment.
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VI.

State Level Response- New Jersey

Governor Chris Christie Administration

New Jersey is one out of ten states that has legislation that limits opioid prescriptions to 7
days or less.159 In February 2017, Governor Chris Christie signed into law one of the toughest laws
aimed at curbing the opioid epidemic,160 which limits the initial opioid prescription to a 5-day
supply for treatment of acute pain and only for the lowest effective dose of immediate-release
opioid drug, making New Jersey the first and only state with the most restrictive limit.161 The law
also mandated that state regulated health insures cover the first 4 weeks of substance abuse
treatment without requiring pre-authorization, a requirement that takes weeks to complete.162 In
addition, prior to prescribing opioids for acute or chronic pain, practitioners must document a
thorough medical history that includes patients’ response to non-opioid medications as well as any
history of substance abuse.163 The law does not apply to patients who receive cancer treatment,
hospice care or are a resident at a long-term care facility.164
While legal prescriptions for opioids has significantly declined in New Jersey, the number
of overdose deaths continues to rise based on data from the CDC.165 This increase is largely
attributed to an increase in the use of synthetic drugs that are analogues to opioids, such as heroin
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and fentanyl.166 Thus, the focus should not be solely on limiting the number of prescription opioids
but also tackling the problem from a broad spectrum such as educating prescribers in their practice
and expanding their training in medication-assisted treatment.167
Governor Phil Murphy Administration
More recently, under Governor Phil Murphy’s administration, New Jersey has continued
the efforts to strengthen opioid-related laws.168 As part of the ongoing efforts of the state to help
battle the nationwide opioid epidemic, in July of 2019 Governor Murphy signed into law threeopioid related laws.169 First, effective February 1, 2020, a pharmacists, other than those dispensing
to an institutional pharmacy, will be required to affix to opioid medication containers a warning
label or sticker describing the risks associated with opioid medications.170 One of the primary
sponsors of this bill, Assemblyman John Armato, called it a necessary tool in the arsenal that would
serve as a cost-effective means of increasing awareness and education about the effects of opioid
abuse.171 Second, a new law now requires that the Department of Human Services provide
individuals who are on Medicaid access to opioid addiction treatment medications like methadone,
buprenorphine, naltrexone and naloxone without any prior authorization requirements.172 Finally,
in an effort to raise awareness about opioid abuse and heroin addiction, Governor Murphy signed
a law that designates October 6th of each year as “Knock Out Opioid Abuse Day”.173
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The efforts to address the opioid epidemic on a state level in theory seem promising and
only time will tell what impact it may have, but in practice it leaves important questions
unanswered. For instance, there are laws like those that Governor Murphy signed, which now
facilitate the accessibility of medication-assisted treatment for Medicaid insured individuals with
opioid addiction without going through the tedious process of getting preauthorization.
Unfortunately, more clinics than primary doctors, are offering the medication-assisted
treatments.174 Dr. Lewis Nelson, chair of the Department of Emergency Medicine at Rutgers New
Jersey Medical School says, “It’s kind of paradoxical in a way that you don’t need any sort of
licensing, other than a DEA number, to prescribe an opioid, but you need this whole training
program and a special license to prescribe a treatment for opioid addiction, buprenorphine.”175
This concern has led to primary doctors not wanting to engage in providing medication-assisted
treatment because of a fear of the “type of clientele” that it may bring into their office practice.176
Opioid addiction has become a public health problem nationwide, but the issue continues to be
approached as an area outside of the medical profession field, where there is no required
coursework in the curriculum for medical schools or even psychology and social work.177 Dr.
Alicia Agnoli, a family practice doctor at University of California Davis, suggests that one way to
approach the stigma is by demystifying addiction treatment and culturally shifting addiction
treatment away from what historically has not been part of the primary care practice. 178 For
instance, Rutgers Medical School has become first in the nation to equip its graduates with the
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federal certification required to provide medication assisted treatment.179 While medical schools
throughout the nation have slowly started to implement opioid addiction treatment into the
curricula, many of the programs still do not include the federal certification process.180

VII.

Conclusion

The response to the opioid epidemic and drug abuse has shifted since the “war on drugs”
was first declared by President Nixon. The way federal and state law have approached the opioid
addiction has shifted from a punitive approach to a public health approach. The response to the
opioid crisis has been considerably more benign, focusing more on prevention, treatment, and
rehabilitation rather criminalizing or imposing harsher sentences. However, it is still too early to
know with certainty how effective the various laws will be in addressing the opioid crisis. What
we have seen so far is that implementation of programs like the PDMP’s or strict limits on
prescription drugs have actually increased overdose death rates. While we see more efforts to
educate and bring awareness to the problem of opioid addiction, there is still a stigma surrounding
opioid addiction and the medical profession has not been entirely on board with recognizing the
need to implement training on opioid treatment into the curricula. The issue has to be looked at
through the lens of opioid addiction as an illness rather than as moral or personal weakness before
we can see significant progress in combating the opioid epidemic.

179

Lilo H. Stainton, Rutgers Med First In U.S. to Offer Certified Medication-Assisted Treatment, NJ Spotlight, (Feb.
28, 2018), https://www.njspotlight.com/2018/02/18-02-27-rutgers-med-first-in-u-s-to-teach-medication-assistedtreatment/.
180
Id.

Carola B. Marquez

26

